Accentia Biopharmaceuticals Announces Favorable Interim Blinded
Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial
for Chronic Sinusitis
TAMPA, Fla.--(BUSINESS WIRE)--Jun 28, 2007 - Accentia
Biopharmaceuticals, Inc. (NASDAQ: ABPI) announced on Wednesday,
June 27 at the Jefferies Healthcare Conference that its interim
analysis of the blinded data on the first fifty patients in the
Fast-Tracked Phase 3 clinical study of SinuNase(TM), ...
Accentia Biopharmaceuticals Scientific Presentations Demonstrate
Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at
the Annual Meeting of the American Academy of Allergy, Asthma, and
who believe they may be eligible to participate in a clinical trial
are encouraged to visit
www.accentia.net/patients/trials_sinunase.php, or c... is under clinical development to treat chronic
sinusitis (rhinosinusitis). sinunase
is a novel application and
formulation of a known anti-fungal exclusively l...
Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable
Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical
Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma
...ies. The Company's lead product candidate is SinuNase(TM), a
novel application and formulation of a known therapeutic to treat
chronic rhinosinusitis. sinunase
has been granted Fast Track status
by the FDA and it is currently in a pivotal Phase 3 clinical trial.
During this fiscal year, the Company also plans...